Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 10/20 | 0.79 |
| ▸ | DRD2 | P14416 | 3/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7875480 | 1.00 | HTR1A (0.79) | HTR1ADRD2CYP2D6TSHRSLC6A2 | |
| SCHEMBL7876193 | 1.00 | HTR1A (0.79) | HTR1ADRD2CYP2D6TSHRSLC6A2 | |
| SCHEMBL7883659 | 1.00 | HTR1A (0.79) | HTR1ADRD2CYP2D6TSHRSLC6A2 | |
| Bromide SCHEMBL11896324 | 0.99 | HTR1A (0.77) | HTR1ADRD2CYP2D6TSHRSLC6A2 | |
| Bromide SCHEMBL241387 | 0.99 | HTR1A (0.77) | HTR1ADRD2CYP2D6TSHRSLC6A2 | |
| Bromide SCHEMBL11895998 | 0.99 | HTR1A (0.77) | HTR1ADRD2CYP2D6TSHRSLC6A2 | |
| Bromide SCHEMBL11896070 | 0.99 | HTR1A (0.77) | HTR1ADRD2CYP2D6TSHRSLC6A2 | |
| Bromide SCHEMBL240055 | 0.99 | HTR1A (0.77) | HTR1ADRD2CYP2D6TSHRSLC6A2 | |
| SCHEMBL7877455 | 0.92 | HTR1A (0.67) | HTR1ADRD2 | |
| SCHEMBL239251 | 0.92 | HTR1A (0.67) | HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196889-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2012-08-02 | — | — | US | disclosed |
| US-20120196889-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2012-08-02 | — | — | US | disclosed |
| WO-2010097087-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196889-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | COMT, ADRB3, ADRB1 | HTR1A 210/4885DRD2 184/4885CYP2D6 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.